Key facts
- It has raised $13.8M; the latest was Secondary Transaction - Private in Apr 2026.
- Notable investors include Yinxinggu Capital, Tailong VC, Proxima Ventures (China), Sanjie Investment Group, Anjie Investment — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Ruidi Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Ruidi Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ruidi Biotechnology
Developer of electromagnetic tumour treatment technologies designed to enable minimally invasive tumour ablation using pulsed electric field energy. The company offers nanosecond pulse tumour ablation systems and digital psychological and behavioural assessment platforms with pulse technology, enabling healthcare providers to achieve more effective tumour treatment and reduced tissue invasion.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Employees
- 16
- Website
- r-ablation.com/
- Ownership
- Privately Held (backing)
Ruidi Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruidi Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruidi Biotechnology in its N-PORT filings yet. We sweep new filings monthly.